Michael Davidson to Anticholesteremic Agents
This is a "connection" page, showing publications Michael Davidson has written about Anticholesteremic Agents.
Connection Strength
17.177
-
Impact of Obicetrapib on Major Adverse Cardiovascular Events in High-Risk Patients: A Pooled Analysis. J Am Coll Cardiol. 2025 Oct 07; 86(14):1046-1056.
Score: 0.834
-
Impact of Batoclimab Treatment on LDL-C with and Without Coadministration of Atorvastatin: Results from a Phase I Randomized Study in Healthy Participants. Drug Saf. 2025 Sep; 48(9):993-1004.
Score: 0.814
-
Obicetrapib exhibits favorable physiochemical and pharmacokinetic properties compared to previous cholesteryl ester transfer protein inhibitors: An integrated summary of results from non-human primate studies and clinical trials. Pharmacol Res Perspect. 2024 Dec; 12(6):e70010.
Score: 0.792
-
The Effect of Proprotein Convertase Subtilisin/Kexin Type 9 Inhibition on Sterol Absorption Markers in a Cohort of Real-World Patients. J Cardiovasc Pharmacol Ther. 2019 01; 24(1):54-61.
Score: 0.507
-
Efficacy and Safety of Alirocumab in High-Risk Patients With Clinical Atherosclerotic Cardiovascular Disease and/or Heterozygous Familial Hypercholesterolemia (from 5 Placebo-Controlled ODYSSEY Trials). Am J Cardiol. 2018 04 15; 121(8):940-948.
Score: 0.493
-
Can We Cure Atherosclerosis? Rev Cardiovasc Med. 2018; 19(S1):S20-S24.
Score: 0.490
-
PCSK9 Inhibitors: Mechanism of Action, Efficacy, and Safety. Rev Cardiovasc Med. 2018; 19(S1):S31-S46.
Score: 0.490
-
Role of Ezetimibe in Lipid-Lowering and Cardiovascular Disease Prevention. Curr Atheroscler Rep. 2015 Dec; 17(12):72.
Score: 0.424
-
Effects of omega-3 carboxylic acids on lipoprotein particles and other cardiovascular risk markers in high-risk statin-treated patients with residual hypertriglyceridemia: a randomized, controlled, double-blind trial. Lipids Health Dis. 2015 Sep 02; 14:98.
Score: 0.417
-
Dyslipidaemia: PCSK9 antibodies: a dividend of the genomics revolution. Nat Rev Cardiol. 2013 Nov; 10(11):618-9.
Score: 0.364
-
Mipomersen, an apolipoprotein B synthesis inhibitor, reduces atherogenic lipoproteins in patients with severe hypercholesterolemia at high cardiovascular risk: a randomized, double-blind, placebo-controlled trial. J Am Coll Cardiol. 2013 Dec 10; 62(23):2178-84.
Score: 0.363
-
Inhibition of intestinal cholesterol absorption with ezetimibe increases components of reverse cholesterol transport in humans. Atherosclerosis. 2013 Oct; 230(2):322-9.
Score: 0.362
-
The efficacy of colesevelam HCl in the treatment of heterozygous familial hypercholesterolemia in pediatric and adult patients. Clin Ther. 2013 Aug; 35(8):1247-52.
Score: 0.361
-
Study design, rationale, and baseline characteristics: evaluation of fenofibric acid on carotid intima-media thickness in patients with type IIb dyslipidemia with residual risk in addition to atorvastatin therapy (FIRST) trial. Cardiovasc Drugs Ther. 2012 Aug; 26(4):349-58.
Score: 0.337
-
Therapies targeting exogenous cholesterol uptake: new insights and controversies. Curr Atheroscler Rep. 2011 Feb; 13(1):95-100.
Score: 0.303
-
Focusing on high-density lipoprotein for coronary heart disease risk reduction. Cardiol Clin. 2011 Feb; 29(1):105-22.
Score: 0.303
-
A 50-week extension study on the safety and efficacy of colesevelam in adults with primary hypercholesterolemia. Am J Cardiovasc Drugs. 2010; 10(5):305-14.
Score: 0.281
-
Statin and ezetimibe combination therapy in cardiovascular disease. Curr Opin Endocrinol Diabetes Obes. 2009 Apr; 16(2):183-8.
Score: 0.267
-
Hypercholesterolemia treatment patterns and low-density lipoprotein cholesterol monitoring in patients with a diagnosis of atherosclerosis in clinical practice. Am J Med. 2009 Jan; 122(1 Suppl):S51-9.
Score: 0.263
-
Is it over for ezetimibe? Expert Rev Cardiovasc Ther. 2008 Jul; 6(6):781-3.
Score: 0.254
-
Is ezetimibe/simvastatin no better than simvastatin alone? Lessons learned and clinical implications. Cleve Clin J Med. 2008 Jul; 75(7):479-82, 486-8, 490-1.
Score: 0.254
-
Should every patient with diabetes receive a statin? Pol Arch Med Wewn. 2008 Jul-Aug; 118(7-8):398-401.
Score: 0.254
-
Combination therapy with ezetimibe and simvastatin to achieve aggressive LDL reduction. Expert Rev Cardiovasc Ther. 2006 Jul; 4(4):461-76.
Score: 0.221
-
Ethnic differences in achievement of cholesterol treatment goals. Results from the National Cholesterol Education Program Evaluation Project Utilizing Novel E-Technology II. J Gen Intern Med. 2006 Apr; 21(4):320-6.
Score: 0.217
-
Results of the National Cholesterol Education (NCEP) Program Evaluation ProjecT Utilizing Novel E-Technology (NEPTUNE) II survey and implications for treatment under the recent NCEP Writing Group recommendations. Am J Cardiol. 2005 Aug 15; 96(4):556-63.
Score: 0.208
-
Real-World Effectiveness and Safety of Evinacumab in Children and Adults With Homozygous Familial Hypercholesterolemia: A Multisite US Perspective-Brief Report. Arterioscler Thromb Vasc Biol. 2025 Jul; 45(7):1310-1315.
Score: 0.205
-
Safety and Efficacy of Obicetrapib in Patients at High Cardiovascular Risk. N Engl J Med. 2025 Jul 03; 393(1):51-61.
Score: 0.204
-
Fixed-dose combination of obicetrapib and ezetimibe for LDL cholesterol reduction (TANDEM): a phase 3, randomised, double-blind, placebo-controlled trial. Lancet. 2025 05 17; 405(10491):1757-1768.
Score: 0.204
-
Cholesteryl ester transfer protein inhibition: a pathway to reducing risk of morbidity and promoting longevity. Curr Opin Lipidol. 2024 Dec 01; 35(6):303-309.
Score: 0.196
-
Efficacy and safety of ezetimibe coadministered with statins: randomised, placebo-controlled, blinded experience in 2382 patients with primary hypercholesterolemia. Int J Clin Pract. 2004 Aug; 58(8):746-55.
Score: 0.193
-
Emerging therapeutic strategies for the management of dyslipidemia in patients with the metabolic syndrome. Am J Cardiol. 2004 Jun 03; 93(11A):3C-11C.
Score: 0.191
-
Obicetrapib on top of maximally tolerated lipid-modifying therapies in participants with or at high risk for atherosclerotic cardiovascular disease: rationale and designs of BROADWAY and BROOKLYN. Am Heart J. 2024 08; 274:32-45.
Score: 0.190
-
Newer pharmaceutical agents to treat lipid disorders. Curr Cardiol Rep. 2003 Nov; 5(6):463-9.
Score: 0.184
-
Efficacy of simvastatin and ezetimibe in treating hypercholesterolemia. J Am Coll Cardiol. 2003 Jul 16; 42(2):398-9; author reply 399.
Score: 0.180
-
Obicetrapib plus ezetimibe as an adjunct to high-intensity statin therapy: A randomized phase 2 trial. J Clin Lipidol. 2023 Jul-Aug; 17(4):491-503.
Score: 0.178
-
Ezetimibe: a novel option for lowering cholesterol. Expert Rev Cardiovasc Ther. 2003 May; 1(1):11-21.
Score: 0.177
-
Cholesterol-lowering drugs bring benefits to high-risk populations even when LDL is normal. J Cardiovasc Nurs. 2003 Jan-Mar; 18(1):44-9; quiz 75-6.
Score: 0.173
-
Ezetimibe coadministered with simvastatin in patients with primary hypercholesterolemia. J Am Coll Cardiol. 2002 Dec 18; 40(12):2125-34.
Score: 0.173
-
Comparison of effects on low-density lipoprotein cholesterol and high-density lipoprotein cholesterol with rosuvastatin versus atorvastatin in patients with type IIa or IIb hypercholesterolemia. Am J Cardiol. 2002 Feb 01; 89(3):268-75.
Score: 0.163
-
A multiple-dose pharmacodynamic, safety, and pharmacokinetic comparison of extended- and immediate-release formulations of lovastatin. Clin Ther. 2002 Jan; 24(1):112-25.
Score: 0.162
-
Effectiveness of colesevelam hydrochloride in decreasing LDL cholesterol in patients with primary hypercholesterolemia: a 24-week randomized controlled trial. Mayo Clin Proc. 2001 Oct; 76(10):971-82.
Score: 0.159
-
Low-dose combination therapy with colesevelam hydrochloride and lovastatin effectively decreases low-density lipoprotein cholesterol in patients with primary hypercholesterolemia. Clin Cardiol. 2001 Jun; 24(6):467-74.
Score: 0.155
-
Efficacy and safety of combination simvastatin and colesevelam in patients with primary hypercholesterolemia. Am J Med. 2001 Apr 01; 110(5):352-60.
Score: 0.153
-
Colesevelam hydrochloride: a non-absorbed, polymeric cholesterol-lowering agent. Expert Opin Investig Drugs. 2000 Nov; 9(11):2663-71.
Score: 0.149
-
Consensus Statement by the American Association of Clinical Endocrinologists and American College of Endocrinology on the Management of Dyslipidemia and Prevention of Cardiovascular Disease Algorithm - 2020 Executive Summary. Endocr Pract. 2020 Oct; 26(10):1196-1224.
Score: 0.148
-
Lipid-altering efficacy and safety of simvastatin 80 mg/day: worldwide long-term experience in patients with hypercholesterolemia. Nutr Metab Cardiovasc Dis. 2000 Oct; 10(5):253-62.
Score: 0.148
-
Reducing residual cardiovascular risk with novel therapies. Curr Opin Lipidol. 2020 04; 31(2):108-110.
Score: 0.143
-
Associations between lower levels of low-density lipoprotein cholesterol and cardiovascular events in very high-risk patients: Pooled analysis of nine ODYSSEY trials of alirocumab versus control. Atherosclerosis. 2019 09; 288:85-93.
Score: 0.136
-
Lipoprotein(a) reductions from PCSK9 inhibition and major adverse cardiovascular events: Pooled analysis of alirocumab phase 3 trials. Atherosclerosis. 2019 09; 288:194-202.
Score: 0.135
-
Effectiveness of atorvastatin for reducing low-density lipoprotein cholesterol to National Cholesterol Education Program treatment goals. Am J Cardiol. 1997 Aug 01; 80(3):347-8.
Score: 0.119
-
A comparison of estrogen replacement, pravastatin, and combined treatment for the management of hypercholesterolemia in postmenopausal women. Arch Intern Med. 1997 Jun 09; 157(11):1186-92.
Score: 0.118
-
Comparison of one-year efficacy and safety of atorvastatin versus lovastatin in primary hypercholesterolemia. Atorvastatin Study Group I. Am J Cardiol. 1997 Jun 01; 79(11):1475-81.
Score: 0.118
-
The efficacy and six-week tolerability of simvastatin 80 and 160 mg/day. Am J Cardiol. 1997 Jan 01; 79(1):38-42.
Score: 0.114
-
Reductions in Atherogenic Lipids and Major Cardiovascular Events: A Pooled Analysis of 10 ODYSSEY Trials Comparing Alirocumab With Control. Circulation. 2016 Dec 13; 134(24):1931-1943.
Score: 0.113
-
Effects of anacetrapib on plasma lipids in specific patient subgroups in the DEFINE (Determining the Efficacy and Tolerability of CETP INhibition with AnacEtrapib) trial. J Clin Lipidol. 2015 Jan-Feb; 9(1):65-71.
Score: 0.098
-
Fluvastatin administration at bedtime versus with the evening meal: a multicenter comparison of bioavailability, safety, and efficacy. Am J Med. 1994 Jun 06; 96(6A):37S-40S.
Score: 0.096
-
Fluvastatin Long-Term Extension Trial (FLUENT): summary of efficacy and safety. Am J Med. 1994 Jun 06; 96(6A):41S-44S.
Score: 0.096
-
Use of microsomal triglyceride transfer protein inhibitors in patients with homozygous familial hypercholesterolemia: translating clinical trial experience into clinical practice. Rev Cardiovasc Med. 2014; 15(1):1-10.
Score: 0.093
-
One-year efficacy and safety of rosuvastatin + fenofibric acid combination therapy in patients with mixed dyslipidemia: evaluation of dose response. Am J Cardiovasc Drugs. 2012 Apr 01; 12(2):117-25.
Score: 0.082
-
Efficacy and safety of dalcetrapib in type 2 diabetes mellitus and/or metabolic syndrome patients, at high cardiovascular disease risk. Diabetes Obes Metab. 2012 Jan; 14(1):30-9.
Score: 0.080
-
Safety and efficacy of ezetimibe added on to rosuvastatin 5 or 10 mg versus up-titration of rosuvastatin in patients with hypercholesterolemia (the ACTE Study). Am J Cardiol. 2011 Aug 15; 108(4):523-30.
Score: 0.077
-
Safety of anacetrapib in patients with or at high risk for coronary heart disease. N Engl J Med. 2010 Dec 16; 363(25):2406-15.
Score: 0.075
-
Update on CETP inhibition. J Clin Lipidol. 2010 Sep-Oct; 4(5):394-8.
Score: 0.073
-
Low-density lipoprotein cholesterol reduction and goal achievement with ezetimibe/simvastatin versus atorvastatin or rosuvastatin in patients with diabetes, metabolic syndrome, or neither disease, stratified by National Cholesterol Education Program risk category. Metab Syndr Relat Disord. 2009 Dec; 7(6):601-10.
Score: 0.070
-
Focus on HDL as a therapeutic target for CAD risk reduction. Am J Cardiol. 2009 Nov 16; 104(10 Suppl):1E-2E.
Score: 0.070
-
Novel nonstatin strategies to lower low-density lipoprotein cholesterol. Curr Atheroscler Rep. 2009 Jan; 11(1):67-70.
Score: 0.066
-
A review of the current status of the management of mixed dyslipidemia associated with diabetes mellitus and metabolic syndrome. Am J Cardiol. 2008 Dec 22; 102(12A):19L-27L.
Score: 0.066
-
Atherosclerosis surrogate imaging trials come of age: for better or for worse? Curr Cardiol Rep. 2008 Nov; 10(6):521-5.
Score: 0.065
-
Efficacy and safety of ABT-335 (fenofibric acid) in combination with rosuvastatin in patients with mixed dyslipidemia: a phase 3 study. Atherosclerosis. 2009 May; 204(1):208-15.
Score: 0.065
-
The effect of darapladib on plasma lipoprotein-associated phospholipase A2 activity and cardiovascular biomarkers in patients with stable coronary heart disease or coronary heart disease risk equivalent: the results of a multicenter, randomized, double-blind, placebo-controlled study. J Am Coll Cardiol. 2008 Apr 29; 51(17):1632-41.
Score: 0.063
-
Niacin use and cutaneous flushing: mechanisms and strategies for prevention. Am J Cardiol. 2008 Apr 17; 101(8A):14B-19B.
Score: 0.063
-
Reducing the residual risk of 3-hydroxy-3-methylglutaryl coenzyme a reductase inhibitor therapy with combination therapy. Am J Cardiol. 2008 Apr 17; 101(8A):27B-35B.
Score: 0.063
-
The use of colesevelam hydrochloride in the treatment of dyslipidemia: a review. Expert Opin Pharmacother. 2007 Oct; 8(15):2569-78.
Score: 0.060
-
Reduced treatment success in lipid management among women with coronary heart disease or risk equivalents: results of a national survey. Am Heart J. 2006 Nov; 152(5):976-81.
Score: 0.056
-
Lipid-altering efficacy of the ezetimibe/simvastatin single tablet versus rosuvastatin in hypercholesterolemic patients. Curr Med Res Opin. 2006 Oct; 22(10):2041-53.
Score: 0.056
-
Comparison of the lipid-modifying efficacy and safety profiles of ezetimibe coadministered with simvastatin in older versus younger patients with primary hypercholesterolemia: a post Hoc analysis of subpopulations from three pooled clinical trials. Clin Ther. 2006 Jun; 28(6):849-59.
Score: 0.055
-
A comparison of Canadian and American guidelines for lipid management using data from the National Cholesterol Education Program Evaluation ProjecT Utilizing Novel E-technology (NEPTUNE) II survey. Can J Cardiol. 2006 Mar 15; 22(4):315-22.
Score: 0.054
-
Cholesterol absorption blockade with ezetimibe. Curr Drug Targets Cardiovasc Haematol Disord. 2005 Dec; 5(6):455-62.
Score: 0.053
-
Use of a treatment algorithm to achieve NCEP ATP III goals with atorvastatin. J Cardiovasc Pharmacol. 2005 Nov; 46(5):594-9.
Score: 0.053
-
Combination therapy in the management of complex dyslipidemias. Curr Opin Lipidol. 2004 Aug; 15(4):423-31.
Score: 0.048
-
Guiding Dyslipidemia Treatment: A Population Pharmacokinetic-Pharmacodynamic Framework for Obicetrapib. J Clin Pharmacol. 2024 Sep; 64(9):1150-1164.
Score: 0.048
-
Lipid and apolipoprotein ratios: association with coronary artery disease and effects of rosuvastatin compared with atorvastatin, pravastatin, and simvastatin. Am J Cardiol. 2003 Mar 06; 91(5A):20C-23C; discussion 23C-24C.
Score: 0.044
-
Combination therapy for dyslipidemia: safety and regulatory considerations. Am J Cardiol. 2002 Nov 20; 90(10B):50K-60K.
Score: 0.043
-
Management of hypercholesterolaemia in postmenopausal women. Drugs Aging. 2002; 19(3):169-78.
Score: 0.040
-
Comparison of the efficacy of atorvastatin versus cerivastatin in primary hypercholesterolemia. Am J Cardiol. 2001 Sep 15; 88(6):635-9.
Score: 0.040
-
Aggressive versus moderate lipid-lowering therapy in postmenopausal women with hypercholesterolemia: Rationale and design of the Beyond Endorsed Lipid Lowering with EBT Scanning (BELLES) trial. Am Heart J. 2001 May; 141(5):722-6.
Score: 0.039
-
Reduction of LDL cholesterol in patients with primary hypercholesterolemia by SCH 48461: results of a multicenter dose-ranging study. J Clin Pharmacol. 2001 Jan; 41(1):70-8.
Score: 0.038
-
Safety profiles for the HMG-CoA reductase inhibitors: treatment and trust. Drugs. 2001; 61(2):197-206.
Score: 0.038
-
A comparison of simvastatin and atorvastatin up to maximal recommended doses in a large multicenter randomized clinical trial. Curr Med Res Opin. 2001; 17(1):43-50.
Score: 0.038
-
Comparison of effects of simvastatin versus atorvastatin on high-density lipoprotein cholesterol and apolipoprotein A-I levels. Am J Cardiol. 2000 Jul 15; 86(2):221-3.
Score: 0.037
-
Aggressive Lipid-Lowering Initiation Abates New Cardiac Events (ALLIANCE)-rationale and design of atorvastatin versus usual care in hypercholesterolemic patients with coronary artery disease. Am J Cardiol. 2000 Jul 15; 86(2):250-2.
Score: 0.037
-
High-molecular-weight hydroxypropylmethylcellulose taken with or between meals is hypocholesterolemic in adult men. J Nutr. 2000 Jul; 130(7):1705-10.
Score: 0.036
-
Lipid-altering efficacy and safety of simvastatin 80 mg/day: long-term experience in a large group of patients with hypercholesterolemia. World Wide Expanded Dose Simvastatin Study Group. Clin Cardiol. 2000 Jan; 23(1):39-46.
Score: 0.035
-
Cholesterol lowering with high-viscosity hydroxypropylmethylcellulose. Am J Cardiol. 1999 Nov 15; 84(10):1198-203.
Score: 0.035
-
Efficacy and safety of lovastatin in adolescent males with heterozygous familial hypercholesterolemia: a randomized controlled trial. JAMA. 1999 Jan 13; 281(2):137-44.
Score: 0.033
-
Lower On-Treatment Low-Density Lipoprotein Cholesterol and Major Adverse Cardiovascular Events in Women and Men: Pooled Analysis of 10 ODYSSEY Phase 3 Alirocumab Trials. J Am Heart Assoc. 2018 09 18; 7(18):e009221.
Score: 0.032
-
Efficacy and safety of simvastatin 80 mg/day in hypercholesterolemic patients. The Expanded Dose Simvastatin U.S. Study Group. Am J Cardiol. 1998 Aug 01; 82(3):311-6.
Score: 0.032
-
The cost of reaching National Cholesterol Education Program (NCEP) goals in hypercholesterolaemic patients. A comparison of atorvastatin, simvastatin, lovastatin and fluvastatin. Pharmacoeconomics. 1998 Jul; 14(1):59-70.
Score: 0.032
-
Cost effectiveness of treatment to National Cholesterol Education Panel (NCEP) targets with HMG-CoA reductase inhibitors. Trial design. Pharmacoeconomics. 1997 Aug; 12(2 Pt 2):278-85.
Score: 0.030
-
Cost-effectiveness of pravastatin in secondary prevention of coronary artery disease. Am J Cardiol. 1996 Aug 15; 78(4):409-14.
Score: 0.028
-
Efficacy and safety of a new HMG-CoA reductase inhibitor, atorvastatin, in patients with hypertriglyceridemia. JAMA. 1996 Jan 10; 275(2):128-33.
Score: 0.027
-
A psyllium-enriched cereal for the treatment of hypercholesterolemia in children: a controlled, double-blind, crossover study. Am J Clin Nutr. 1996 Jan; 63(1):96-102.
Score: 0.027
-
Evaluation of lipids, drug concentration, and safety parameters following cessation of treatment with the cholesteryl ester transfer protein inhibitor anacetrapib in patients with or at high risk for coronary heart disease. Am J Cardiol. 2014 Jan 01; 113(1):76-83.
Score: 0.023
-
Diagnosis and treatment of familial hypercholesterolaemia. Eur Heart J. 2013 Apr; 34(13):962-71.
Score: 0.022